Big news from the global biopharmaceutical world: Zhuhai Trinomab Therapeutics Co., Ltd. (“Trinomab Therapeutics”) has officially announced they have marketing approval from the National Medical Products Administration (NMPA) of China for Sintetol® (generic name: Siltartoxatug Injection, also known as TNM002). This is a first-in-class recombinant anti-tetanus toxin monoclonal antibody drug, marking a major step forward in how we fight this disease This achievement in the treatment of tetanus is a great example of how important and powerful scientific contributions can be in driving real-world breakthroughs, with a big assist in this case coming from Revvity’s CHOSOURCE™ expression platform.
A new era in tetanus treatment
Sintetol® is an innovative, groundbreaking new biologic that’s been designed to stop tetanus toxin in its tracks with high efficiency. Unlike traditional treatments, it uses advanced antibody engineering to block the toxin's neurotoxic effects at an early stage, giving doctors a critical new tool to treat and even prevent the disease. Tetanus remains a serious and potentially fatal disease, but with Sintetol® there’s a new clinical option. It has the potential to make a real difference and change the way tetanus is managed, ultimately improving outcomes for patients around the world.
The role of Revvity’s CHOSOURCE expression platform
Behind Sintetol®’s successful launch is some powerful technology: Revvity’s CHOSOURCE, a CHO-based expression platform that played a critical role in advancing drug development and bringing this drug to life. CHOSOURCE expression platform makes it possible to produce high-yield, high-quality recombinant proteins efficiently, without sending development costs sky high. It’s a major reason innovative treatments like this can make it out of the lab and into the clinic.
Speaking with Dr. Bing Xie, Revvity’s Director of Strategic Licensing, for the People Republic of China, he emphasized that:
“The CHOSOURCE expression platform is a core driver of innovation in biologics at Revvity. We are honored to partner with Trinomab Therapeutics and witness the journey of Sintetol® from lab to market. Moving forward, we will deepen our support to accelerate the development of more groundbreaking therapies and bring hope to patients around the world.”
What’s next for Trinomab Therapeutics?
There’s no doubt that the launch of Sintetol® is a huge achievement and milestone, but it’s only the beginning. Trinomab is advancing with a robust and exciting pipeline, including drugs targeting RSV, nerve growth factor, varicella-zoster virus, and human cytomegalovirus. Some of these are already in Phase I and III trials in China and the U.S., putting the company well on its way to becoming a global leader in monoclonal antibody therapeutics.
This has also been a great example of the innovation that can be achieved when scientific companies come together. Revvity and Trinomab Therapeutics are raising the bar in biologics, combining robust and adaptable drug development platforms with bold scientific vision to help shape the future of disease treatment.
The CHOSOURCE Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.
